Who are Sapresta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levoamlodipine, Dl-Prenylamine, Coniel, Zanidip, Cinalong, Zanidip.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aranidipine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sapresta — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sapresta (ARANIDIPINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: aranidipine. Area: Cardiovascular.

phase 2 aranidipine Voltage-gated L-type calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Sapresta (ARANIDIPINE). Aranidipine works by blocking the L-type calcium channel, which reduces the amount of calcium entering the heart and blood vessels, leading to lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sapresta TARGET	ARANIDIPINE		phase 2	aranidipine	Voltage-gated L-type calcium channel
Levoamlodipine	LEVAMLODIPINE		marketed	levamlodipine	Voltage-gated L-type calcium channel	2019-01-01
Dl-Prenylamine	PRENYLAMINE		marketed	prenylamine	Sodium channel alpha subunits; brain (Types I, II, III), Calmodulin, Voltage-gated L-type calcium channel
Coniel	BENIDIPINE		marketed	benidipine	Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel
Zanidip	Zanidip	Lee's Pharmaceutical Limited	marketed		Voltage-gated L-type calcium channel
Cinalong	CILNIDIPINE		phase 3	cilnidipine	Voltage-dependent N-type calcium channel subunit alpha-1B, Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel
Zanidip	LERCANIDIPINE		phase 3	lercanidipine	Voltage-gated L-type calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (aranidipine class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sapresta — Competitive Intelligence Brief. https://druglandscape.com/ci/aranidipine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing